A 53-year old non-smoking Thai female was diagnosed with metastatic non-small cell lung cancer to bone. The initial biopsy from the bone lesion showed metastatic adenocarcinoma. She achieved partial response after treatments with radiation therapy to the bones, followed by 6 cycles of combination chemotherapy. About 4 months later, recurrence of the pulmonary and osseous disease was apparent. She has ECOG performance status of 3. Gefitinib 250 mg/day was administered until disease progression for about 14 months. After 6 weeks on this therapy, she had dramatic improvement of all symptoms including her performance status and had nearly complete resolution of all pulmonary lesions. Tolerability was good, with only mild fatigue. The overall survival was 28 months. This illustrates that gefitinib could produce significant clinical benefits in selected Thai patients even with poor performance status. This result is consistent with previous reports that the clinical characteristics of female, non-smoker and adenocarcinoma histology seem to predict response to gefitinib.
Download full-text PDF |
Source |
---|
Neurosurg Rev
January 2025
Kobayashi Hospital, 510 Imaichi, Izumo City, Shimane, 693-0001, Japan.
Adverse effects of advanced age and poor initial neurological status on outcomes of patients with aneurysmal subarachnoid hemorrhage (SAH) have been documented. While a predictive model of the non-linear correlation between advanced age and clinical outcome has been reported, no previous model has been validated. Therefore, we created a prediction model of the non-linear correlation between advanced age and clinical outcome by machine learning and validated it using a separate cohort.
View Article and Find Full Text PDFSupport Care Cancer
January 2025
Oral Diagnosis Department, Faculdade de Odontolodia de Piracicaba, Universidade de Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
Purpose: Oral mucositis (OM) reflects a complex interplay of several risk factors. Machine learning (ML) is a promising frontier in science, capable of processing dense information. This study aims to assess the performance of ML in predicting OM risk in patients undergoing head and neck radiotherapy.
View Article and Find Full Text PDFPediatr Radiol
January 2025
Department of Radiology, College of Medicine, University of Florida, PO Box 100374, Gainesville, FL, 32610-0374, USA.
Purpose: To evaluate whether adult and pediatric trauma center status, as well as the presence of dedicated child protection teams, influences radiology resident performance in detecting non-accidental trauma on the Emergent/Critical Care Imaging Simulation (WIDI SIM) exam.
Materials And Methods: We retrospectively analyzed 639 WIDI SIM exam scores for four pediatric non-accidental trauma cases completed by radiology residents across 33 programs. Residents were stratified by level (R1-R4) and institutional factors, including adult trauma center status, pediatric trauma center status, and child protection team presence.
Background: Pediatric ultrasound (US)-guided percutaneous liver biopsy is a commonly performed procedure in children, and may be performed in a variety of clinical settings. However, there is little research on the relative costs associated with different sedation methods and locations.
Objective: This study uses time-driven activity-based costing (TDABC) to identify relevant costs associated with different biopsy sedation techniques and locations to help inform providers and patients as well as guide value-conscious care.
Pediatr Radiol
January 2025
Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Background: Radiographic skeletal survey plays an important role in the diagnosis of infant abuse. Some practitioners have expressed concerns about the radiation exposure from this examination.
Objective: To utilize state-of-the-art hybrid computational phantoms to more accurately estimate radiation doses of skeletal surveys performed for suspected infant abuse.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!